根据名称进行药物检索

Adriamycin 与 Cyclosporine oral/injection

Adriamycin 与 Cyclosporine oral/injection互相作用以及同时服用的可能性。

检测结果:

Adriamycin <> Cyclosporine oral/injection

现实性: 03.06.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用霉素一起孢菌素，可能增加的影响霉素。联系您的医生，如果你经历极端疲劳，容易出血或血、黑色、血腥或迟延凳子,发烧,寒战，心跳不规则、腹痛、黄皮肤或眼睛，严重恶心、呕吐、腹泻和食欲不振。如果你的医生，并规定这些药物在一起，可能需要的剂量调整或特别的测试安全地使用这两种药物。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

调节剂:孢菌素可以显着降低的等离子隙两性霉素，其主要代谢产物，doxorubicinol. 在抗药性的细胞、细胞内积累的霉素不会发生，因为多药耐药-1(MDR-1)基因的产品，一种膜糖蛋白，是一种能源的依赖外流泵。 Cyclosporine块的功能这个水泵，从而允许更大的细胞内积累的一些细胞毒性剂。

管理：这种相互作用可以用于临床优点在于治疗癌症。如果药是用来减少肿瘤细胞抗霉素，建议霉素的剂量将减少到大约50%到60%的通常建议的剂量。

来源

Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA "The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer." Cancer 74 (1994): 834-41
Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI "Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance." J Clin Oncol 12 (1994): 835-42
Tidefelt U, Juliusson G, Elmhorn-Rosenborg A, Peterson C, Paul C "Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A." Eur J Haematol 52 (1994): 276-82
Scheulen ME, Budach W, Skorzec M, Wiefelsputz JK, Seeber S "Influence of cyclosporin A on the pharmacokinetics and pharmacodynamics of doxorubicin (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a12711993
Klaff RA "The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer." Cancer 75 (1995): 1215-6
Bartlett NL, Fisher GA, Halsey J, Ehsan MN, Lum BL, Sikic BI "A Phase I trial of doxorubicin (D) with cyclosporine (CsA) as a modulator of multidrug resistance (MDR)." Proc Annu Meet Am Soc Clin Oncol 12 (1993): a366
Barbui T, Rambaldi A, Parenzan L, Zucchelli M, Perico N, Remuzzi G "Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy." Lancet 339 (1992): 1421
Larsson R, Bergh J, Nygren P "Combination of cyclosporin A and buthionine sulfoximine (BSO) as a pharmacological strategy for circumvention of multidrug resistance in small cell lung cancer cell lines selected for resistance to doxorubicin." Anticancer Res 11 (1991): 455-9
Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, et al "Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON." Lancet 340 (1992): 255-9
Hu XF, Martin TJ, Bell DR, de Luise M, Zalcberg JR "Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines." Cancer Res 50 (1990): 2953-7
Shoji Y, Fisher MH, Periasamy A, et al "Verapamil and cyclosporin A modulate doxorubicin toxicity by distinct mechanisms." Cancer Lett 57 (1991): 209-18
Colombo T, Zucchetti M, D'Incalci M "Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats." J Pharmacol Exp Ther 269 (1994): 22-7